Patents Assigned to NACUITY PHARMACEUTICALS, INC
  • Treatment of age-related macular degeneration, glaucoma, and diabetic retinopathy with n-acetylcysteine amide (NACA) or (2R,2R?)-3,3?-disulfanediyl BIS(2-acetamidopropanamide)(DiNACA)
    Patent number: 11766413
    Abstract: The present invention includes a method for the treatment of age-related macular degeneration, glaucoma, or diabetic retinopathy in a human that comprises administering to the human a therapeutically effective amount of N-acetylcysteine amide (NACA) or (2R,2R?)-3,3?-disulfanediyl bis(2-acetamidopropanamide) (diNACA) sufficient to treat or reduce the symptoms of the age-related macular degeneration, glaucoma, or diabetic retinopathy.
    Type: Grant
    Filed: January 9, 2020
    Date of Patent: September 26, 2023
    Assignee: Nacuity Pharmaceuticals, Inc.
    Inventor: G. Michael Wall
  • Methods of making deuterium-enriched N-acetylcysteine amide (d-NACA) and (2R, 2R?)-3,3?-disulfanediyl bis(2-acetamidopropanamide) (diNACA) and using d-NACA and diNACA to treat diseases involving oxidative stress
    Patent number: 11753370
    Abstract: The present invention includes pharmaceutical composition comprising (2R,2R?)-3,3?-disulfanediyl bis(2-acetamidopropanamide)(diNACA) or D3-N-acetyl cysteine amide, or a physiologically acceptable salt thereof, having a deuterium enrichment above the natural abundance of deuterium, and derivatives or solids thereof, and methods of using diNACA to treat eye diseases and other diseases associated with oxidative damage including, e.g., antivenom, beta-thallassemia, cataract, chronic obstructive pulmonary disease, macular degeneration, contrast-induced nephropathy, asthma, lung contusion, methamphetamine-induced oxidative stress, multiple sclerosis, Parkinson's disease, platelet apoptosis, Tardive dyskinesia, Alzheimer disease, HIV-1-associated dementia, mitochondrial diseases, myocardial myopathy, neurodegenerative diseases, pulmonary fibrosis, skin pigmentation, skin in need of rejuventation, antimicrobial infection, Friedreich's ataxia.
    Type: Grant
    Filed: July 14, 2020
    Date of Patent: September 12, 2023
    Assignee: Nacuity Pharmaceuticals, Inc.
    Inventor: G. Michael Wall
  • Method for preparation of n-acetyl cysteine amide and derivatives thereof
    Patent number: 11548851
    Abstract: The present invention includes methods for making and isolating N-acetylcysteine amide, (2R,2R?)-3,3?-disulfanediyl bis(2-acetamidopropanamide, diNACA), intermediates and derivatives thereof comprising: contacting cystine with an alcohol and a chlorinating reagent to form an organic solution containing L-cystine dimethylester dihydrochloride; combining dried or undried L-cystine dimethylester dihydrochloride with a triethylamine, an acetic anhydride, and an acetonitrile to form a di-N-acetylcystine dimethylester; mixing dried di-N-acetylcystine dimethylester with ammonium hydroxide to form a di-N-acetylcystine amide (diNACA); and separating dried di-N-acetylcystine dimethylester into N-acetylcysteine amide with dithiothreitol, triethylamine and an alcohol.
    Type: Grant
    Filed: July 2, 2021
    Date of Patent: January 10, 2023
    Assignee: NACUITY PHARMACEUTICALS, INC.
    Inventors: G. Michael Wall, Douglas G. Johnson, Anja Rubenstein, Rodney Tucker, Josh Bolger
  • Method for preparation of N-acetyl cysteine amide and derivatives thereof
    Patent number: 10590073
    Abstract: The present invention includes methods for making and isolating N-acetylcysteine amide, intermediates and derivatives thereof comprising: contacting cystine with an alcohol and a chlorinating reagent to form an organic solution containing L-cystine dimethylester dihydrochloride; combining dried or undried L-cystine dimethylester dihydrochloride with a triethylamine, an acetic anhydride, and an acetonitrile to form a di-N-acetylcystine dimethylester; mixing dried di-N-acetylcystine dimethylester with ammonium hydroxide to form a di-N-acetylcystine amide; and separating dried di-N-acetylcystine dimethylester into N-acetylcysteine amide with dithiothreitol, triethylamine and an alcohol.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: March 17, 2020
    Assignee: NACUITY PHARMACEUTICALS, INC.
    Inventors: G. Michael Wall, Doug Johnson, Anja Rubenstein, Rodney Tucker, Josh Bolger
  • Method for the preparation of N-acetyl cysteine amide
    Patent number: 9889103
    Abstract: The present application discloses an efficient process for the preparation of N-acetyl-L-cysteine amide (NACA) starting with N-acetyl-L-cysteine.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: February 13, 2018
    Assignee: NACUITY PHARMACEUTICALS, INC.
    Inventors: John C. Warner, Srinavasa Cheruku, Sambaiah Thota, John W. Lee
  • Method for preparation of N-acetyl cysteine amide
    Patent number: 9763902
    Abstract: The present application discloses an efficient process for the preparation of N-acetyl-L-cysteine amide (NACA) starting with N-acetyl-L-cysteine.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: September 19, 2017
    Assignee: NACUITY PHARMACEUTICALS, INC
    Inventors: John C. Warner, Srinavasa Cheruku, Sambaiah Thota, John W. Lee